Solid Biosciences (SLDB) announced that it has received Fast Track designation from the U.S. Food and Drug Administration, FDA, for SGT-212, the Company’s, AAV-based gene therapy candidate for the treatment of Friedreich’s ataxia. SGT-212 will deliver the full-length frataxin gene via dual routes of administration incorporating intradentate nucleus, IDN, and intravenous infusions, designed to promote restoration of therapeutic levels of the frataxin protein to address neurologic, cardiac and systemic clinical manifestations of FA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences initiated with a Buy at Truist
- Closing Bell Movers: Cal-Maine Foods up 5% on Q2 results
- Solid Biosciences gains 12% to $4.40 on FDA clearance of SGT-212 IND
- Solid Biosciences announces FDA clearance of SGT-212 IND application
- Solid Biosciences reports inducement grants under Nasdaq listing rule
Questions or Comments about the article? Write to editor@tipranks.com